
Andera Partners co-leads $118m Series B of Mineralys thx (USA)
Mineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being...

XNK Therapeutics AB raises €12.75m
XNK Therapeutics said it will use the proceeds to accelerate an investigator-initiateed open Phase II study with its autologous NK cell-based...

Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...
Commission to establish EU health data space
The EU Commission is set to present a draft law on a "European health data area" this Tuesday, which could be a big thing for digital...

Evotec signs contracts with Almirall and Sernova
Under the alliance Evotec is set to discover novel targets or therapeutics for skin diseases such as atopic dermatitis or basal cell carcinoma....

$50m for London CHARM Therapeutics for deep minded folding expertise
London based CHARM Therapeutics rushes into the 3D deep-learning space with a $50M Series A financing co-led by F-Prime Capital and OrbiMed, with...

Roche obtains special authorisation for bispecific antibody
Roches new developed immunotherapy is based on a bispecific antibody, which targets B-lymphocyte antigen CD20 and the CD3-T-cell receptor at the...